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Minority Pediatric Patients with Inflammatory Bowel Disease
Demonstrate an Increased Length of Stay
Edward L. Barnes, MD, MPH,* Bharati Kochar, MD,* Millie D. Long, MD, MPH,*,†
Christopher F. Martin, MSPH,*,† and Michael D. Kappelman, MD, MPH†,‡
Background: Genetic and other biological factors may lead to differences in disease behavior among children with inflammatory bowel disease of
different races, which may be further modified by disparities in care delivery. Using the Kids’ Inpatient Database, we aimed to evaluate differences in the
management of pediatric patients with inflammatory bowel disease by race, focusing on length of stay (LOS).
Methods: We performed a cross-sectional analysis using 2000 to 2012 data from the Kids’ Inpatient Database, a nationally representative database. We
identified pediatric patients (#18 years of age) with discharge diagnoses of Crohn’s disease (CD) or ulcerative colitis (UC). We used multivariable
logistic regression to evaluate the relationship between race and LOS, controlling for age, payer status need for surgery, and year of admission.
Results: We identified 27,295 hospitalizations for children with inflammatory bowel disease (62% CD and 38% UC), Compared with white patients
with CD, black (adjusted odds ratio 1.37; 95% confidence interval, 1.22–1.53; P , 0.001) and Hispanic patients (adjusted odds ratio: 1.37; 95%
confidence interval: 1.19–1.59; P , 0.001) with CD demonstrated increased odds of a LOS greater than the 75th percentile. When compared with white
patients with UC, Hispanic patients also demonstrated increased odds of a LOS greater than the 75th percentile (adjusted odds ratio: 1.20; 95%
confidence interval, 1.02–1.42, P ¼ 0.015).
Conclusions: After controlling for age, year of admission, and clinical phenotypes, black and Hispanic patients with CD and Hispanic patients with UC
had longer LOS than white patients. These may be due to differences in provider/hospital characteristics, socioeconomic differences, and/or differences in
genetics and other biological factors (see Video Abstract, Supplemental Digital Content 1, http://links.lww.com/IBD/B656).
(Inflamm Bowel Dis 2017;23:2189–2196)
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E pidemiologic data regarding the incidence and prevalence ofinflammatory bowel disease (IBD) among racial groups in the
United States are relatively limited. Although emerging literature
suggests that the genetic determinants of IBD may differ by race1
leading to differences in disease presentation, these biological factors
may be further modified by disparities in care delivery. Despite
the fact that black patients are suspected to have an overall lower
prevalence of IBD in the United States, previous studies have sug-
gested that black patients are more likely to experience IBD-related
hospitalizations and higher IBD-related mortality when compared
with non-Hispanic white and Hispanic populations.2 In addition,
although black race has been associated with an increased likelihood
of significant health care expenditures related to IBD,3 in other eval-
uations, black patients were less likely to receive therapy with inflix-
imab4 and thiopurines5 when compared with white patients. Similarly,
Hispanic patients are less likely to receive therapy with biologics and
immunomodulators when compared with white patients.6
In addition to differences in utilization patterns among patients
of different races with IBD, racial differences in severity of disease
have also been demonstrated. In particular, black patients with IBD
have been suggested to have increased rates of perianal disease7,8 and
upper GI tract Crohn’s disease (CD).7 Differences in disease extent
and severity have also been noted between patients of different races
with ulcerative colitis (UC), with black patients being more likely to
demonstrate proctitis or left-sided colitis when compared with white
patients with UC.4,9–11 Among Hispanic patients with IBD in the
United States, an increased prevalence of UC has been reported,12–16
with foreign-born Hispanic patients demonstrating significantly more
UC than US-born Hispanics and non-Hispanic white patients.6 An
evaluation of a large integrated health plan also demonstrated a sig-
nificant increase in incident cases of UC among Hispanic children
over an 11-year period.17
Most of the literature examining racial differences in the
treatment of IBD includes studies that have been conducted in adult
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index hospitalization. Race was defined using a uniform coding
provided by HCUP, where Hispanic patients were uniquely iden-
tified as a separate group and not using a Hispanic modifier code.
ICD-9-CM diagnosis codes were used to identify additional clin-
ical factors suggested to be independent predictors or confounders
of the relationship between IBD and LOS, including the presence
of perianal disease among patients with CD, which has been
suggested to differ between patients of different races. In addition,
we evaluated the presence of fistulizing CD, given our suspicion
that CD complicated by a fistula may be associated with increased
LOS. For patients with CD, we limited the IBD-related surgery
definition to ICD-9-CM coding for abdominal surgeries only
(including a previously reported definition for intestinal resec-
tion,21 see Table 1, Supplemental Digital Content 2, http://links.
lww.com/IBD/B643). We excluded perianal procedures. For pa-
tients with UC, surgery was defined using previously reported
ICD-9-CM coding for colectomy22 (see Table 1, Supplemental
Digital Content 2, http://links.lww.com/IBD/B643).
Given that comorbidities can also play a significant role in
risk for hospitalization and LOS, we included the Charlson
comorbidity index in our multivariable analyses.23 Although not
developed for use in pediatric populations, this index has been
widely used, including in the evaluation of children.24,25 In addi-
tion, we adjusted for concomitant infection using a composite
outcome created from the most common infections described in
previous studies of immunosuppressed patients with IBD and
autoimmune disorders.26–28 We also evaluated hospital teaching
status and IBD-related hospital volume. For the evaluation of
IBD-related hospital volume, we used previously identified cut-
offs from KID of low- and high-volume centers (#20 admissions
annually and .20 admissions annually).29 However, because of
a high correlation between teaching status and IBD-related hos-
pital volume, only hospital teaching status was included in our
final models.
Statistical Analysis
All analyses were performed using survey procedures in
SAS version 9.4 (SAS Institute, Cary, NC) to account for the
complex survey design. These survey procedures also allowed for
data to be weighted to reflect estimates of the national population,
including the means and proportions presented. We used Chi-
Square test and Student’s t test to compare proportions and con-
tinuous variables, respectively. We separated LOS values into
quartiles, and then used logistic regression modeling to estimate
the unadjusted odds of a LOS greater than the 75th percentile for
the covariates of interest.
Based on clinical knowledge and previously reported risk
factors for increased LOS, multivariable logistic regression
models were then constructed to evaluate the association between
risk factors and a LOS greater than the 75th percentile, adjusting
for potential confounders. All factors were included in the model
due to their clinical relevance, including payer and hospital-
specific factors, and all factors ultimately included in the final
models were identified a priori. Given our suspicion for
populations. However, racial disparities in the treatment of IBD 
have been suggested in pediatric patients, including increased risk 
of hospital readmission and longer LOSs among black children 
with IBD,18 as well as lower rates of parenteral nutrition.19 Given 
these suggestions of differences in both disease presentation and 
health care resource utilization between white, black, and Hispanic 
patients with IBD, we used a nationwide inpatient database of 
pediatric patients to evaluate the presentation and management 
of children with IBD in the United States. We focused on length 
of stay (LOS) as a primary outcome while attempting to identify 
differences in phenotype of disease, hospitalization type, and payer 
status among patients with IBD of different races.
METHODS
Data Source
We performed a cross-sectional analysis using 2000 to 
2012 data from the Kids’ Inpatient Database (KID), a nationally 
representative sample of pediatric hospitalizations from the 
Healthcare Cost and Utilization Project (HCUP). The KID is 
the largest publicly available all-payer pediatric inpatient database 
from the United States that includes data from 15,235,214 hospi-
talizations from 2000 to 2012. Using data from up to 44 states 
depending on the year analyzed, the KID is designed to be nation-
ally representative of hospitalization rates and characteristics for 
all payers and the uninsured. The KID contains over 100 clinical 
and nonclinical variables,20 up to 15 International Classification 
of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) 
diagnostic and procedure codes, hospital characteristics, and out-
comes including hospital LOS, and total charges. Because of the 
de-identified nature of the data, this study was determined exempt 
from review by the Institutional Review Board of the University 
of North Carolina.
Study Sample
We examined discharge data from hospitalizations of 
patients aged 18 years and younger. Any hospitalization with an 
ICD-9-CM diagnosis code indicating CD (555.xx) or UC (556.xx) 
as 1 of the first 3 indications for admission was eligible for 
inclusion in this study. To minimize misclassification of sub-
groups of IBD (CD or UC), we excluded hospitalizations with 
discharge codes for both CD and UC (n ¼ 3187).
Outcome of Interest
The primary outcome of interest, hospital LOS, was 
determined by evaluating discharge data of individual hospital-
izations using data from the KID.
Covariates
During the index admission, multiple covariates associated 
with a patient’s underlying IBD or perceived risk of an increased 
LOS were evaluated. Patient demographics were analyzed, 
including age, sex, race, and primary insurance/payer for the
differential LOSs among surgical and nonsurgical hospitaliza-
tions, we also performed secondary analyses where patients who
underwent an IBD-related surgery were evaluated separately. A 2-
tailed P-value of 0.05 was chosen as the threshold for statistical
significance for all tests. Odds ratios (ORs) and 95% confidence
intervals (CIs) are presented.
RESULTS
We identified 27,295 hospitalizations of patients with IBD
in the 2000 to 2012 KID database (62% CD, 38% UC). Using the
KID weighting, these represented 27,034 hospitalizations of
patients with CD and 16,247 hospitalizations of patients with UC.
Among hospitalized patients with CD, black patients were
more likely to have a diagnosis of perianal disease and were more
likely to be discharged from a teaching hospital when compared
with white and Hispanic patients (Table 1). When compared with
hospitalized white patients with CD, black and Hispanic patients
were less likely to undergo an IBD-related surgery during the
admission (Fig. 1) and were more likely to have Medicaid insur-
ance (Table 1). Among hospitalized patients with UC, similar
patterns were demonstrated (Table 2), although 59% of black
patients with UC were females.
Among all hospitalizations of patients with IBD, the
median LOS was 3.59 days (interquartile range
[IQR]:1.81–6.51). For patients with CD, the median LOS
was 3.39 days (IQR: 1.69–6.11). The median LOS was 3.93
days for patients with UC (IQR: 2.03–7.12). The median LOS
for white patients with CD was 3.35 days (IQR: 1.66–5.95).
Compared with white patients with CD, the median LOS was
longer for black (3.87 days, IQR: 2.01–6.99, P , 0.001) and
Hispanic patients with CD (3.72 days, IQR: 1.78–7.10, P ,
0.001). The median LOS was significantly longer among His-
panic patients with UC (4.32 days, IQR: 2.23–7.84) when com-
pared with white patients with UC (3.92 days, IQR: 2.06–7.13,
P ¼ 0.007). There was no significant difference when compar-
ing the median LOS among black and white patients with UC
(3.98 versus 3.92 days, P ¼ 0.186).
TABLE 1. Baseline Demographics, Clinical, and Hospital Characteristics Among All Patients with CD in Kids’
Inpatient Database 2000 to 2012, Stratified by Racial Group
White, n ¼ 12,137 Black, n ¼ 2630 Hispanic, n ¼ 1335 Other, n ¼ 916
Pn % n % n % n %
Age, yrs ,0.001
#6 375 3 60 2 96 7 60 7
7–12 2544 21 570 21 349 26 235 27
12–18 9218 76 2000 76 890 67 621 66
Female 5893 49 1280 49 580 44 375 41 ,0.001
Presence of perianal disease 422 3 139 5 51 4 38 4 ,0.001
Presence of a fistula 450 4 87 3 35 3 28 3 0.129
Obese 119 1 56 2 32 2 8 1 ,0.001
IBD-related abdominal surgery 1597 13 262 10 101 8 88 9 ,0.001
Concomitant infectiona 385 3 106 4 48 4 25 3 0.157
Charlson comorbidity score ,0.001
0 10,881 89 2213 85 1125 84 820 90
1 1150 9 395 14 185 14 84 9
$2 106 1 22 1 25 2 12 1
Discharged from teaching hospital 9003 74 2176 83 1053 81 745 81 ,0.001
Hospital region ,0.001
Northeast 3803 31 662 24 417 31 311 33
Midwest 2587 22 521 20 52 4 139 13
South 3781 32 1197 46 536 41 265 24
West 1966 16 250 10 330 26 201 30
Payer status ,0.001
Medicaid 1907 16 1191 46 588 44 275 30
Private insurance 9477 78 1220 46 600 46 552 60
Other 731 6 216 8 144 11 89 10
aInfection defined as Clostridium difficile, meningitis, encephalitis, endocarditis, pneumonia, pyelonephritis, septic arthritis, osteomyelitis, septicemia or bactermia, or cellulitis.
In both unadjusted analysis and after adjusting for age,
perianal disease, fistulizing disease, payer status, admission to
a teaching hospital, hospital region, IBD-related surgery,
concomitant infection, Charlson comorbidity index score, and
year of admission, black patients with CD demonstrated increased
odds of a hospital LOS greater than the 75th percentile (adjusted
OR [aOR] 1.37, 95% CI:1.22–1.53, P , 0.001) as did Hispanic
patients (aOR: 1.37, 95% CI, 1.19–1.59, P , 0.001) when com-
pared with white patients with CD. In addition to minority race,
perianal or fistulizing disease, Medicaid insurance, admission to
a teaching hospital, and an IBD-related surgery during the admis-
sion were all associated with increased LOS (Table 3). When
stratified into surgical and nonsurgical admissions, similar pat-
terns were demonstrated. When compared with hospitalized white
patients with CD, black patients with CD demonstrated increased
odds of a LOS greater than the 75th percentile in both nonsurgical
(aOR: 1.34; 95% CI, 1.18–1.52, P , 0.001) and surgical admis-
sions (1.48; 95% CI, 1.10–2.01, P ¼ 0.012, see Table 2, Supple-
mental Digital Content 3, http://links.lww.com/IBD/B644).
Hispanic patients with CD also demonstrated an increase in odds
of a longer LOS in nonsurgical admissions when compared with
white patients with CD (aOR: 1.36; 95% CI, 1.16–1.59, P , 0.
001), although there was no significant difference when evaluat-
ing surgical admissions (see Table 2, Supplemental Digital Con-
tent 3, http://links.lww.com/IBD/B644).
FIGURE 1. Comparison of IBD-related surgery among patients of different
races in the Kids’ Inpatient Database 2000 to 2012; for white versus black
comparisons, all P, 0.001; for white versus Hispanic comparisons, all P,
0.001; for black versus Hispanic CD-related abdominal surgery, P ¼ 0.016;
for black versus Hispanic colectomy for UC, P ¼ 0.731.
TABLE 2. Baseline Demographics, Clinical, and Hospital Characteristics Among All Patients with UC in Kids’
Inpatient Database 2000 to 2012, Stratified by Racial Group
White, n ¼ 7254 Black, n ¼ 1096 Hispanic, n ¼ 1190 Other, n ¼ 737
Pn % n % n % n %
Age, yrs ,0.001
#6 505 7 60 6 78 9 97 13
7–12 1599 22 272 24 304 26 192 25
12–18 5150 71 764 70 808 65 448 62
Female 3750 52 633 58 608 51 357 48 ,0.001
Obese 97 1 29 2 23 2 ,11 1 0.001
Colectomy 660 9 54 5 69 6 53 7 ,0.001
Concomitant infectiona 166 2 35 3 32 3 23 3 0.075
Charlson comorbidity Score ,0.001
0 6573 91 916 84 1049 88 670 91
1 591 8 162 15 121 10 55 7
$2 90 1 18 2 20 2 12 2
Discharged from teaching hospital 5425 74 879 80 613 74 598 81 ,0.001
Hospital region ,0.001
Northeast 2102 29 226 21 215 18 247 34
Midwest 1601 23 238 21 66 5 103 14
South 2077 29 512 47 383 32 174 24
West 1474 19 120 11 526 44 213 29
Payer status ,0.001
Medicaid 1141 16 486 45 528 44 205 29
Private insurance 5716 79 530 48 521 44 459 61
Other 383 5 77 7 113 9 73 10
aInfection defined as Clostridium difficile, meningitis, encephalitis, endocarditis, pneumonia, pyelonephritis, septic arthritis, osteomyelitis, septicemia or bactermia, or cellulitis.
When evaluating the odds of a LOS greater than the 75th
percentile among patients with UC, only Hispanic patients
demonstrated a significant increase in odds compared with white
patients with UC in both the unadjusted and adjusted analyses
TABLE 3. Unadjusted and Adjusted Analysis, Odds of
a Length of Stay Greater Than the 75th Percentile













Black 1.36 (1.22–1.50) 1.37 (1.22–1.53)
Hispanic 1.33 (1.16–1.52) 1.37 (1.19–1.59)
Other racial groups 1.34 (1.14–1.57) 1.39 (1.18–1.64)
Age, yrs 0.280
#6 1.07 (0.86–1.32) 1.09 (0.87–1.35)
7–12 Reference Reference
12–18 1.05 (0.96–1.15) 0.95 (0.86–1.05)
Perianal disease 1.18 (0.98–1.42) 1.40 (1.16–1.69) ,0.001
Fistulizing disease 4.00 (3.33–4.82) 2.35 (1.90–2.92) ,0.001
Payer status
Medicaid 1.12 (1.03–1.22) 1.12 (1.02–1.23) 0.021




1.67 (1.51–1.85) 1.70 (1.52–1.89) ,0.001
Hospital region ,0.001
Northeast 0.84 (0.74–0.95) 0.79 (0.71–0.89)
Midwest 1.07 (0.98–1.17) 0.66 (0.57–0.76)





3.98 (3.58–4.43) 3.87 (3.47–4.31) ,0.001






1 0.90 (0.79–1.01) 0.97 (0.85–1.10)
$2 1.06 (0.73–1.53) 1.21 (0.83–1.77)
Year ,0.001
2000 1.20 (1.04–1.39) 1.24 (1.07–1.44)
2003 0.95 (0.84–1.09) 0.98 (0.85–1.12)
2006 Reference Reference
2009 0.96 (0.85–1.07) 0.97 (0.86–1.09)
2012 0.83 (0.75–0.93) 0.79 (0.70–0.89)
All variables included in final multivariable analysis are listed above.
aPatients with length of stay .75th percentile by race: white 2947; black 1825; Hispanic
406; and other 273.
bInfection defined as Clostridium difficile, meningitis, encephalitis, endocarditis, pneu-
monia, pyelonephritis, septic arthritis, osteomyelitis, septicemia or bactermia, or cellulitis.
TABLE 4. Unadjusted and Adjusted Analysis, Odds of
a Length of Stay Greater Than the 75th Percentile













Black 0.99 (0.86–1.15) 1.08 (0.92–1.28)
Hispanic 1.16 (1.01–1.34) 1.20 (1.02–1.42)
Other racial
groups
1.22 (1.02–1.45) 1.34 (1.11–1.61)
Age, yrs 0.117
#6 0.97 (0.80–1.17) 1.02 (0.83–1.25)
7–12 Reference Reference
12–18 0.87 (0.78–0.97) 0.90 (0.79–1.01)
Payer Status 0.093
Medicaid 1.08 (0.98–1.20) 1.11 (0.98–1.25)




1.87 (1.65–2.11) 1.61 (1.40–1.84) ,0.001
Hospital region ,0.001
Northeast 0.91 (0.80–1.04) 0.91 (0.80–1.05)
Midwest 0.72 (0.61–0.84) 0.70 (0.59–0.83)
South 0.81 (0.71–0.92) 0.83 (0.73–0.96)
West Reference Reference
Colectomy 7.32 (6.15–8.70) 5.61 (4.72–6.66) ,0.001






1 0.96 (0.81–1.13) 1.00 (0.84–1.19)
$2 1.44 (1.00–2.09) 1.40 (0.95–2.06)
Year 0.184
2000 1.10 (0.92–1.31) 1.16 (0.96–1.41)
2003 1.04 (0.89–1.22) 1.01 (0.84–1.21)
2006 Reference Reference
2009 0.94 (0.82–1.08) 1.02 (0.87–1.19)
2012 0.93 (0.82–1.07) 0.93 (0.80–1.08)
All variables included in final multivariable analysis are listed above.
aPatients with length of stay .75th percentile by race: white 1844; black 286; Hispanic
341; and other 219.
bInfection defined as Clostridium difficile, meningitis, encephalitis, endocarditis, pneu-
monia, pyelonephritis, septic arthritis, osteomyelitis, septicemia or bactermia, or cellulitis.
limited to single center reports,32 with smaller sample sizes or
have evaluated socioeconomic and demographic factors other
than race that may lead to health care disparities,33,34 including
hospital and Emergency Department resource utilization.
In our analyses, both black and Hispanic pediatric patients
with IBD were less likely to have an IBD-related surgery during
an inpatient hospitalization when compared with white patients
with IBD, even after adjusting for confounders. In a previous
evaluation, there was no significant difference in abdominal
surgeries or colectomy among black and white pediatric patients
with IBD, despite a significant increase in perianal procedures and
endoscopies.18 In a separate study using data from a prospective
multi-center registry collected at 26 sites, the rate of surgery
among pediatric patients with IBD did not differ by race.35 In
1 study of adults with IBD from a university medical center,
Hispanic patients with UC were less likely to get a colectomy
when compared with white patients, whereas there was no differ-
ence in colectomy rates when comparing black and white patients
with UC.15 Given that we demonstrated a significant difference in
the use of surgery in the management of IBD in our analyses, we
also stratified our population by surgical or nonsurgical admis-
sions to evaluate our primary outcome of LOS.
We should also consider the differences in LOS among
patients with IBD of different racial groups in comparison to
patients with other chronic conditions. When LOS has been
evaluated among patients with asthma and Medicaid insurance,
LOS was similar among hospitalized black and white children
from 33 states.36 However, in an evaluation of children with
systemic lupus erythematosus using the PHIS, Hispanic children
demonstrated a median LOS that was 1 day longer than non-
Hispanic patients.37 In another evaluation of pediatric patients
with chronic comorbidities and Medicaid insurance, black patients
undergoing surgery were more likely to demonstrate increased
LOS as compared to white patients.38
The magnitude of the difference in LOS is also critical to
consider, given the use of a large, nationwide database in this
analysis. Although the median LOSs were significantly longer
among black and Hispanic patients with CD as compared to white
patients with CD, there is a concern that differences of ,0.5 days
may not be clinically meaningful. In studies of other pediatric
diseases such as bronchiolitis, differences in LOS of less than 1
day have been reported as clinically important given their associ-
ation with decreased costs.39 In addition, when comparing those
patients who demonstrated the longest LOSs (those above the
75th percentile), there seem to be more clinically meaningful
differences among patients of different races, particularly among
hospitalizations of patients with CD.
The role that socioeconomic factors play in outcomes of
IBD must not be ignored, given that socioeconomic differences
are likely intertwined with apparent differences in approaches to
treatment and outcomes among patients of different races.
Minority populations such as black and Hispanic patients seem
to be overrepresented among Medicaid and uninsured populations
when evaluating nationwide trends of adults with IBD.40 In our
(aOR: 1.20; 95% CI, 1.02–1.42, P ¼ 0.015). Other significant 
predictors of an increased LOS included a colectomy during the 
admission, discharge from a teaching hospital, and a concomitant 
infection at the time of admission (Table 4). When stratifying by 
whether a colectomy occurred during the admission, Hispanic 
patients demonstrated an increase in odds of a longer LOS when 
compared with white patients with UC when limited to nonsurgi-
cal hospitalizations (aOR: 1.18; 95% CI, 1.00–1.40, P ¼ 0.029). 
However, there were no significant differences in LOS among 
patients of different races when evaluating hospitalizations where 
a surgery occurred (see Table 3, Supplemental Digital Content 4, 
http://links.lww.com/IBD/B645).
DISCUSSION
In a nationally representative sample of pediatric patients 
with IBD, we demonstrated a significant increase in LOS among 
hospitalized black and Hispanic patients with CD when compared 
with hospitalized white patients with CD. In addition, Hispanic 
patients with UC demonstrated a significantly increased LOS 
when compared with white patients with UC. We also demon-
strated lower rates of IBD-related surgery among hospitalized 
black and Hispanic patients with IBD when compared with 
hospitalized white patients with IBD. Black patients and Hispanic 
patients with IBD were more likely to use Medicaid insurance 
when compared with white patients with IBD, and black patients 
were more likely to be discharged from a teaching hospital. When 
we evaluated LOS for IBD by teaching hospital status alone, those 
patients admitted to teaching hospitals demonstrated significantly 
increased LOSs as well.
Our demonstration of an increased LOS among 2 minority 
populations with IBD is similar to a previous evaluation using the 
Pediatric Health Information System (PHIS) that demonstrated an 
increased LOS among black children with CD.18 In their study, 
Dotson, et al18 found that black children had increased frequency 
of perianal disease, anemia, and vitamin D deficiency, in addition 
to an increased LOS and re-admissions after index hospitalization. 
Although we could not evaluate the risk of readmission within 
KID, we did demonstrate an increased LOS among black patients 
with CD and among Hispanic patients with both UC and CD 
using a database that is more nationally representative than the 
PHIS database, where most of the 44 included centers are tertiary 
care centers. In addition, the inclusion of Hispanic patients in our 
analyses would seem to indicate that these potential disparities are 
not limited to the black population of pediatric patients with IBD 
and extend to other minority groups.
Although the potential inequalities in the management of 
IBD among patients of different races has been recognized for 
some time,30 the data investigating potential racial disparities 
among pediatric patients with IBD has been relatively limited. 
In addition to the study using the PHIS database,18 Dotson et al 
used the ImproveCareNow network to demonstrate increased dis-
ease severity among black pediatric patients with IBD as com-
pared to white patients.31 Other previous studies have been
evaluation, we demonstrated that black and Hispanic patients
were much more likely to have Medicaid insurance when com-
pared with white patients with IBD. In addition, patients with
Medicaid were more likely to demonstrate longer LOSs during
admissions of patients with both CD and UC. The role that Med-
icaid insurance plays in outcomes and resource utilization among
patients with IBD has been evaluated in previous studies. Both
Medicaid insurance and minority race have previously been asso-
ciated with decreased odds of undergoing small bowel resection
for CD.41 In an evaluation of patients with UC, black patients
demonstrated a longer wait time to colectomy during hospitaliza-
tion, whereas patients with Medicaid demonstrated a significant
increase in mortality when undergoing colectomy.42 Given these
results among adults with IBD, we must consider the effects that
Medicaid insurance has on outcomes among pediatric patients
with IBD.
In addition to the specific issues associated with Medicaid
insurance, there are other non-IBD related factors that could
influence LOS among black and Hispanic patients. Although we
adjusted for comorbidities and coexisting infection during the
hospitalization, there are other variables that exist which likely
influence LOS that cannot be measured. For example, provider-
related factors including delays in the initiation of appropriate
therapy could also influence LOS. In addition, patient preferences
regarding interventions such as surgery could also lead to
increased LOS, however, these would not be appropriately
captured in an administrative database. Delays in the discharge
process related to arranging appropriate follow-up, outpatient
medications and therapy, and even transportation could all
influence LOS, although these may not be directly related to the
severity of an individual’s IBD. Each of these scenarios could
lead to differences in LOS among patients of different racial
groups and would require further evaluation in future studies to
investigate the potential drivers of disparities in LOS among chil-
dren with IBD.
Although concomitant infection during an admission with
CD or UC seemed to increase an individual’s risk for prolonged
LOS, a patient’s age and the Charlson comorbidity score were not
significant predictors of an increased LOS. Among patients with
CD, all other regions of the country demonstrated a slight
decrease in odds of prolonged LOS when compared with the
West. This was also true when evaluating patients with UC,
although the comparison between the Northeast and West was
not significant.
An important strength of our study was the use of
a nationally representative sample of pediatric patients with
IBD to evaluate disease behavior (such as perianal disease and
fistulizing disease), treatments including utilization of surgery,
and resource utilization patterns including hospital LOS. Our
study has limitations that should also be noted. Despite
demonstrating significant differences in hospital LOS and
IBD-related surgery among pediatric patients with IBD of
different racial groups, we were unable to fully evaluate
disease severity as the KID lacks data on clinical symptoms,
laboratory results, and other test findings. To mitigate this, we
analyzed the effects of more aggressive phenotypes of CD,
perianal disease, and fistulizing CD.43,44 Both were associated
with increased odds of prolonged LOS. However, the validity
of ICD-9 codes for CD-specific phenotypes has not been estab-
lished in the KID database. In evaluations of administrative
databases of adults, a single ICD-10 code has been accurate
in the identification of patients with UC and CD.45 In addition,
the KID database allows for cross-sectional analyses only, and
thus we were unable to evaluate or account for the potential
that a single patient could be admitted multiple times during
the course of the study period. Our inability to evaluate read-
missions is a significant limitation, particularly given that those
patients with the longest LOS are likely the same individuals
who are most likely to be readmitted within 30 or 90 days of
their index hospitalization.
In conclusion, we used a nationally representative sample
of pediatric hospitalizations to demonstrate that black and
Hispanic patients with IBD have increased LOS when compared
with white patients with IBD, despite a lower frequency of IBD-
related surgery for CD and colectomy for UC during inpatient
hospitalizations. These potential disparities in care delivery have
been suggested in other studies, and given that our analyses used
a nationwide sample of both academic and community practice
settings, we feel that these findings should be evaluated further to
determine what effects these disparities may have on other clinical
outcomes among pediatric patients with IBD. Although these
disparities may be due to differences in provider/hospital
characteristics, socioeconomic differences, or differences in
genetic or other biological factors, these warrant further evalua-
tion to potentially improve the care of pediatric patients with CD
and UC.
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